Aceragen, Inc.
Industry
- Biotechnology
- Large Molecule
- Antisense, Oligonucleotides
- Pharmaceuticals
- Specialty Pharmaceuticals
Other Names/Subsidiaries
- Arrevus, Inc.
Latest on Aceragen, Inc.
Sage Therapeutics, Inc. has a lot to figure out in the coming weeks, now that the US Food and Drug Administration has approved Zurzuvae (zuranolone) for postpartum depression (PPD) but rejected the d
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. BMS Calls On SyntheX, Autolus In Protei
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Inks Platform Licensing Agreement
Dyno Therapeutics, Inc. came out of stealth mode a year ago with $9m in seed funding it raised in 2018 and partnerships with Novartis AG and Sarepta Therapeutics, Inc. worth more than $2bn in upf